Current treatment options are limited leaving many patients unhappy

  • Patients are refractory or unsatisfied with medical management1
  • FESS patients can experience uncontrolled rhinitis2
  • Allergy immunotherapy patients can experience continued drainage
  • Multiple devices may be needed to treat all areas
  • Septoplasty and/or turbinectomy alone may only address some symptoms
  • Other ablative technologies have varied patient responses

Comprehensive office-friendly procedure
with RhinAer Stylus

  • Disrupts posterior nasal nerve (PNN) that triggers rhinitis
  • Treats multiple locations
  • Incisionless and can be done under local anesthesia
  • Office-friendly, operating room ready

Aerin Medical RhinAer Stylus treatment
Aerin Medical Aerin System RhinAer Stylus

Clinically proven, durable results

Statistically significant improvement shown in prospective, multicenter study3

  • Both allergic and nonallergic patients
  • ALL four TNSS symptoms
  • Post-nasal drip
  • Chronic cough
  • ALL patient quality of life measures
  • No device-related serious adverse events

Which patients can benefit most from this procedure?

  • Patients with moderate to severe chronic rhinorrhea, post-nasal drip, congestion and/or chronic clearing of the throat
  • Allergy immunotherapy patients with continued drainage
  • Nonallergic chronic rhinitis patients
  • FESS patients with uncontrolled rhinitis

Ready to adopt Aerin into your practice?

AerinTM System fits seamlessly into the office or OR environment. Many payers have coverage policies in place for the treatment of nasal airway obstruction or chronic rhinitis. To learn more, contact Aerin Medical at (833)-484-8237

1 Data on file with Aerin Medical, Aerin quantitative market research.
2 van der Veen J, Seys SF, Timmermans M, Levie P, Jorissen M, Fokkens WJ, et al. Real-life study showing uncontrolled rhinosinusutus after sinus surgery in ateritary referral centre. Allergy. 2017;72(2):282-290.
3 Data on file. RhinAer® Stylus Clinical Study TP668. Endpoint from baseline to 52 weeks..